



health

Department:  
Health  
REPUBLIC OF SOUTH AFRICA



Reference: 2024/10/03/EDP/02

**NOTICE: PUBLICATION OF THE NATIONAL ESSENTIAL MEDICINES LIST COMMITTEE (NEMLC) APPROVED UPDATES TO THE PRIMARY HEALTHCARE (PHC) AND ADULT HOSPITAL LEVEL CHAPTERS FOR THE STANDARD TREATMENT GUIDELINES (STGs) AND ESSENTIAL MEDICINES LIST (EML) – 2024 EDITIONS**

Below is a list of the recently published chapters for the 2024 editions of the PHC and Adult Hospital Level STGs and EML. Updates to chapters and supporting technical documents (medicine reviews, costing reports, NEMLC reports, PHC implementation slides) for the 2024 review cycle are uploaded onto the National Department of Health Knowledge Hub eLibrary and the NHI webpage as they are finalised for publication.

<b>PHC Chapters with the associated NEMLC reports</b>
Chapter 6: Obstetrics and Gynaecology
Chapter 11: HIV and AIDS
Chapter 17: Respiratory Conditions
Chapter 18: Eye Conditions
<b>PHC Level Appendices</b>
Appendix I: Asthma Monitoring <i>(new addition to the PHC STGs and EML)</i>
Appendix II: Devices for respiratory conditions <i>(new addition to the PHC STGs and EML)</i>
<b>PHC implementation slides</b>
Chapter 2: Gastro-intestinal Conditions
Chapter 21: Emergencies and injuries

<b>Adult Hospital Level Chapters with the associated NEMLC reports</b>
Chapter 2: Blood and Blood Forming Agents
Chapter 10: HIV and AIDS
Chapter 16: Respiratory System
Chapter 18: Eye Disorders
<b>Adult Hospital Level Appendices</b>
Appendix V: Asthma Monitoring.
Appendix VI: Devices for Respiratory Conditions <i>(new addition to the Adult Hospital Level STGs and EML)</i>

**NOTICE: PUBLICATION OF THE NATIONAL ESSENTIAL MEDICINES LIST COMMITTEE (NEMLC) APPROVED UPDATES TO THE PRIMARY HEALTHCARE (PHC) AND ADULT HOSPITAL LEVEL CHAPTERS FOR THE STANDARD TREATMENT GUIDELINES (STGs) AND ESSENTIAL MEDICINES LIST (EML) – 2024 EDITIONS**

<b>List of Medicine Reviews and Costing Analyses: Please refer to the individual medicine reviews for the NEMLC recommendation which may/not support inclusion on the EML.</b>		
<b>Topic</b>	<b>Relevance to:</b>	
	<b>PHC Level of Care</b>	<b>Adult Hospital Level of Care</b>
Aspirin for preeclampsia	√	
Aspirin versus LMWH for VTE prophylaxis after trauma-related fractures		√
Atazanavir/ritonavir versus lopinavir/ritonavir for adult HIV patients	√	√
Cabotegravir as PrEP for adults	√	
Corticosteroid-sparing agents for severe uveitis		√
Darunavir/ritonavir vs lopinavir/ritonavir for adult HIV patients	√	√
Dapivirine ring for PrEP	√	
DOACs for VTE prophylaxis in hospitalised adult patients		√
DOACs for the treatment of DVT or PE in hospitalized adult patients		√
Dolutegravir for first-line antiretroviral therapy	√	√
Dolutegravir-containing antiretroviral therapy in patients receiving rifampicin-containing TB treatment	√	
Dolutegravir in pregnant women and women of child-bearing potential	√	√
Fluoroquinolones for MDR TB prophylaxis	√	
Guideline adaptation of NICE Guideline “Venous thromboembolism in over 16s” for patients undergoing total hip arthroplasty or total knee arthroplasty requiring VTE prophylaxis		√
Hyaluronidase for cataract surgery		√
Intraoperative MMC or 5-FU during trabeculectomy for glaucoma management		√
Isoniazid Preventive Therapy in Pregnancy	√	√
LMWH for secondary VTE prophylaxis during pregnancy and the puerperium.		√
Liposomal Amphotericin B for cryptococcal meningitis		√
Oral prednisone/prednisolone for severe bilateral posterior and panuveitis		√
Prophylactic Factor IX compared to on-demand/episodic treatment for patients with severe haemophilia B without inhibitors		√
Prophylactic Factor VIII compared to on-demand treatment for patients (adults and children) with haemophilia A without inhibitors		√
Recycling tenofovir disoproxil fumarate in second line antiretroviral therapy: evidence from NADIA and ARTIST Trials	√	√
Tenofovir Alafenamide for HIV with an addendum included for Hep B non-HIV co-infected patients	√	√
TPT for all household contacts	√	
Adoption of the WHO consolidated guidelines on tuberculosis: Drug-resistant tuberculosis treatment 2022	√	√
<b>Costing Analyses</b>		
Budget Impact Analysis: TB Preventive Therapy for all household contacts.		
Cost effectiveness analysis: Dapivirine ring for PrEP		
Cost effectiveness and budget impact analysis: Cabotegravir as PrEP for adults		
<b>Abbreviations used in the table</b>		
5-FU	Fluorouracil	
DOACs	Direct Oral Anticoagulants	
DVT	Deep Vein Thrombosis	
LMWH	Low Molecular Weight Heparins	
MMC	Mitomycin C	
NICE	National Institute for Health and Care Excellence	
PE	Pulmonary Embolism	
PrEP	Pre-Exposure Prophylaxis	
VTE	Venous Thromboembolism	
TPT	TB Preventive Therapy	
WHO	World Health Organization	

**NOTICE: PUBLICATION OF THE NATIONAL ESSENTIAL MEDICINES LIST COMMITTEE (NEMLC) APPROVED UPDATES TO THE PRIMARY HEALTHCARE (PHC) AND ADULT HOSPITAL LEVEL CHAPTERS FOR THE STANDARD TREATMENT GUIDELINES (STGs) AND ESSENTIAL MEDICINES LIST (EML) – 2024 EDITIONS**

**The corresponding URLs are listed below:**

Knowledge Hub-AHL: <https://knowledgehub.health.gov.za/elibrary/hospital-level-adults-standard-treatment-guidelines-stgs-and-essential-medicines-list-eml>

Knowledge Hub -PHC: <https://knowledgehub.health.gov.za/elibrary/primary-healthcare-phc-standard-treatment-guidelines-stgs-and-essential-medicines-list-eml>

NHI webpage: <https://www.health.gov.za/nhi-edp-stgs-eml/>

These documents will also be available on the EMGuidance application platform in due course. To sign up, click on the link: <http://onelink.to/sy896k>.


Please refer to the chapter, corresponding NEMLC report and evidence-based medicine review/s (where available) for detailed explanations of all the medicines, general measures and editorial amendments made to the STGs and EMLs in the 2020 to 2024 review cycle.

Provinces and Healthcare Facilities are requested to distribute and communicate this information in consultation with the Pharmaceutical and Therapeutics Committees for immediate implementation. Kindly share with all healthcare professionals and relevant stakeholders.

Queries may be submitted via e-mail to:

E-mail: [SAEDP@health.gov.za](mailto:SAEDP@health.gov.za)

Kind regards



**MS K JAMALOODIEN**  
**CHIEF DIRECTOR: SECTOR-WIDE PROCUREMENT**  
**DATE: 03 October 2024**